PUBLISHED DATE : Apr 2020 | Pages : 269
Fill out your details & get your free sample
Premature Ejaculation Market Size, Share, & Trends Analysis Report Research Report by Drug Class (SSRIs, PDE5 Inhibitors, Anesthetic Agents, and Others), Route of Administration (ROA) (Oral PE Therapeutics and Topical PE therapeutics), and Geography (APAC, Europe, North America, Latin America, and Middle East & Africa), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020-2025
269 Pages
54 Tables
155 Charts
5 Regions
19 Countries
15 Companies
3 Market Segment
| Report Attribute | Details |
|---|---|
| Market Size (Revenue) | USD 2 BILLION (2025) |
| CAGR | 8% (2020-2025) |
| Base Year | 2019 |
| Forecast Year | 2020-2025 |
| Market Segments | Drug Class (SSRIs, PDE5 Inhibitors, Anesthetic Agents, and Others), Route of Administration (ROA) (Oral PE Therapeutics and Topical PE therapeutics) |
| Geographic Analysis | APAC, Europe, North America, Latin America, and Middle East & Africa |
| Countries Covered | US, Canada, Germany, France, UK, Italy, Spain, Japan, China, India, South Korea, Brazil, Mexico, Argentina, Turkey, Saudi Arabia, South Africa, and Iran |
The global premature ejaculation (PE) market size will reach USD 2 billion in 2025 is expected to grow at a steady CAGR during the forecast period. The market growth can be mainly attributed to the growing prevalence of premature ejaculation (PE) among men globally. PE is the most prevalent sexual dysfunction among men the world over. With the presence of a single approved oral drug, the PE therapeutics market is dominated by off-label drugs, generic versions of patent expired drugs, and OTC formulations, both regionally as well as globally. The increasing demand for several off-label and generic drugs is a primary factor driving the growth of the market. The treatment with off-label drugs belonging to SSRIs and topical formulations has revolutionized the treatment approach. Several vendors are offering off-label drugs that belong to different drug classes such as SSRIs and PDE5 inhibitors and OTC topical creams/sprays for treatment. Therefore, the demand for such drugs is likely to increase at a steady rate globally.
Another advance is the advent of metered-dose delivery systems. Several OTC anesthetic sprays are formulated to deliver the drug through a metered-dose administration. Metered-dose delivery systems deliver lidocaine and prilocaine in base form without organic solvents. Such drugs can be easily removed before vaginal penetration, thus circumventing the need for a condom that most patients find uncomfortable. Hence, such advanced formulations are likely to boost the future growth of the global PE therapeutics market.
This research report offers a detailed segmentation by
The SSRIs segment is likely to retain its market dominance during the forecast period. SSRIs are considered as effective drugs for the treatment of PE, and they majorly include paroxetine, sertraline, fluoxetine, citalopram, escitalopram, and dapoxetine. Several evidence-based studies have demonstrated the safety and efficacy of SSRIs in delaying ejaculation, which ensures their role as first-line agents for the treatment of lifelong and acquired PE. The growth of the segment is likely to be facilitated by an increase in the number of countries gaining approval for the use of Priligy. The increased recommendation of SSRIs by healthcare professionals is one of the key factors for the growth of the segment worldwide.
The increase in the share of the PDE5 inhibitors segment can be mainly attributed to the brand value of existing PDE5 inhibitor drugs, which facilitate high uptake among patients, especially for self-management. Anesthetic agents have proved effective and are generally tolerated for patients with PE. Several topical anesthetics are inexpensive and readily available from pharmacies, thereby allowing them an easy medication to buy. The segment is likely to witness a higher CAGR during the forecast period than other drug therapies. The expected launch of new licensed/unlicensed OTC products worldwide is the prime factor enhancing growth.
Oral therapeutics consists of tablets, capsules, solutions, and suspensions. Several oral agents, specifically SSRIs, tramadol, and dapoxetine, have proven effective and safe for the treatment of PE. Hence, several HCPs are recommending oral therapeutics as a primary treatment option to manage premature ejaculation. A daily dose of oral therapies has exhibited improved and enhanced efficacy over topical therapies. Therefore, the demand for oral therapeutics is increasing at a steady-state worldwide. Moreover, the growing pervasiveness of PE and the increasing uptake of generic off-label medications are the key factors enabling the growth of the oral ROA segment.
Topical medications refer to the drugs that are applied to the skin and include creams, gels, sprays, powders, emulsion, solutions, and ointments. These drugs are often used as “a needed option” for efficient management of PE and erectile dysfunction. Therefore, the segment accounts for a smaller share than oral therapeutics. Easy availability of several topical medicines at multiple sales channels acts as one of the key factors, which boosts the product uptake of topical therapies in the vast majority of patients.
North America is the major revenue contributor to the global premature ejaculation therapeutics market. The presence of a large disease population, coupled with better access to healthcare, especially OTC drugs, and increased focus on sexual wellness products is the primary factor for high shares. The strong presence of key vendors is also another reason for high product uptake in the region.
The presence of major vendors, better disease awareness, high healthcare spending on sexual wellbeing is the primary factor for high market share in this region. Germany, the UK, France, Italy, and Spain are the major revenue contributors. The increasing treatment-seeking population will mainly drive the market in Europe due to improved PE awareness and increased patient focus on healthy sexual well-being.
A low treatment-seeking population associated with social stigma in select regions, lack of awareness, and comparatively less access to healthcare services, especially in developing countries, are few factors that limit the growth of the market in this region. Japan, India, China, Australia, and South Korea are the major revenue contributors in the region.
The Latin American market is expected to grow at a higher rate than other regions during the forecast period. A high prevalence of PE, improvement in healthcare spending, an increase in awareness, an increase in uptake of drugs, especially generic off-label drugs and low-cost OTC drugs will fuel the growth of premature ejaculation therapeutics market in this region. The prevalence rate of PE in Latin America is estimated to be higher than in Europe. The average prevalence rate in this region is estimated at 28%. However, an increase in disease awareness, willingness to seek professional help for disease management, high prevalence of chronic psychological and other male sexual health disorders, especially ED, are contributing to the growth of the PE therapeutics market in this region.
Low access to healthcare facilities, inadequacy in a number of specialized health professionals, and lack of awareness about the disease and its treatment options are the key reasons for the low market size of premature ejaculation treatment despite high market potential. Therefore, the market is expected to witness slow growth than other regions in the coming years.
The global premature ejaculation therapeutics market is fairly fragmented and is characterized by the presence of both pharmaceutical companies and generic manufacturers offering off-label branded drugs and generics. Vendors are offering off-label drugs, generic versions, and OTC topical anesthetic agents. Companies offering topical anesthetic drug formulations are gaining widespread popularity than manufacturers offering oral PE therapeutics. Pfizer, Bayer, Eli Lilly and Company, and GlaxoSmithKline are also being used as off-label drugs. Therefore, these global players have a significant presence in the market as physicians, especially in select countries such as the US, Germany, and Japan and are prescribing popular brands such as Paxil, Zoloft, Viagra, Levitra, and Cialis as off-label drugs. However, due to their high cost, a broad majority of physicians worldwide are recommending low-cost generic versions of these popular prescription drugs. Therefore, the market has witnessed the entry of many generic manufacturers offering generic drugs of the patent expired drugs at a low price.
Segmentation by Drug Class
By ROA
By Geography
Frequently Asked Questions
What is the global premature ejaculation market size and growth forecast?
Premature ejaculation market size to reach USD 2 billion by 2025, growing at a CAGR of 8% during the forecast period
What are the major factors that are driving the global premature ejaculation market share?
The market growth can be mainly attributed to the growing prevalence of premature ejaculation (PE) among men globally.
Who are the leading vendors in the premature ejaculation market?
Absorption Pharmaceuticals, Innovus Pharmaceuticals, Pfizer, and Plethora Solutions Holdings are leading vendors in the market
Which segment will contribute maximum revenue to the premature ejaculation market?
North America is the major revenue contributor to the global premature ejaculation therapeutics market.
What are the latest industry trends and drivers in the market?
The following factors are likely to contribute to the growth of the premature ejaculation therapeutics market during the forecast period: High Demand for Topical Drug Therapies for PE Treatment, Low Effectiveness of Non-pharmacological PE Treatment, Increasing Awareness Campaigns and Initiatives for PE Treatment, and Advances in PE Drug Formulation Technology
The following factors are likely to contribute to the growth of the premature ejaculation therapeutics market during the forecast period:
Base Year: 2019
Forecast Year: 2020–2025
The study considers the present scenario of the premature ejaculation therapeutics market and its market dynamics for the period 2019−2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent companies operating in the market.
Key Vendors
Other Vendors
Market Segmentation by Drug Class
Market Segmentation by ROA
Market Segmentation by Geography
1 Research Methodology
2 Research Objectives
3 Research Process
4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.3.1 Market Segmentation by Geography
5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation
6 Market at a Glance
7 Introduction
7.1 Premature Ejaculation: An Overview
7.1.1 Definition
7.1.2 Disease Overview
7.1.3 Classification of Premature Ejaculation
7.1.4 Symptoms of PE
7.1.5 Etiology of Premature Ejaculation
7.1.6 Epidemiology
7.2 ISSN Guidelines On Premature Ejaculation
7.2.1 Disease Assessment
7.2.2 Treatment Options For Pe
8 CLINICAL TRIAL LANDSCAPE
8.1 Overview
8.1.1 Subjects Selection Criteria for PE Clinical Trials
8.1.2 Clinical Trial Data Evaluation Considerations
8.1.3 Clinical Trial Design Considerations for PE
8.2 Clinical Trial Endpoints
9 Pipeline Landscape
9.1 Overview
9.2 Key Pipeline Drug candidates
9.3 Key Pipeline Molecules
9.3.1 Epelsiban
9.3.2 IX-01
9.3.3 DA-8031
9.3.4 NH02D
9.4 Terminated/Withdrawn Drug Candidates
10 Market Opportunities & Trends
10.1 High Demand for Topical Drug Therapies for PE Treatment
10.2 Presence of High Unmet Demand
10.3 Advancements in PE Drug Formulation Technology
11 Market Growth Enablers
11.1 Rising Prevalence/Incidence of PE
11.2 Wide Accessibility of OTC Drugs & General Off-label Drugs for PE
11.3 Low effectiveness of Non-pharmacological PE Treatment
11.3.1 Major Drawbacks of Non-Pharmacological Treatments
11.4 Increasing Awareness Campaigns & Initiatives for PE Treatment
12 Market Restraints
12.1 Availability of Alternative Treatment Options for PE
12.2 Low Treatment-Seeking Patient Pool
12.3 Adverse Effects of PE Therapeutics
12.4 Clinical Trial Withdrawals/Terminations & Inactive Clinical Studies
13 Market Landscape
13.1 Market Overview
13.2 Market Size & Forecast
13.3 Five Forces Analysis
13.3.1 Threat of New Entrants
13.3.2 Bargaining Power of Suppliers
13.3.3 Bargaining Power of Buyers
13.3.4 Threat of Substitutes
13.3.5 Competitive Rivalry
14 Premature Ejaculation Therapeutics Market by Drug Class
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 SSRIs
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.4 PDE5 Inhibitors
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.5 Anesthetic Agents
14.5.1 Market Overview
14.5.2 Market Size & Forecast
14.6 Others
14.6.1 Market Overview
14.6.2 Market Size & Forecast
15 Premature Ejaculation Therapeutics Market by Route of Administration
15.1 Market Snapshot & Growth Engine
15.2 Market Overview
15.3 Oral
15.3.1 Market Overview
15.3.2 Market Size & Forecast
15.4 Topical
15.4.1 Market Overview
15.4.2 Market Size & Forecast
16 Premature Ejaculation Therapeutics Market by Geography
16.1 Market Snapshot & Growth Engine
16.2 Overview
17 North America
17.1 Market Overview
17.2 Market Size & Forecast
17.3 Drug Class Segmentation
17.3.1 Market Snapshot & Growth Engine
17.4 KEY COUNTRIES
17.4.1 US: Premature Ejaculation Therapeutics Market Size & Forecast
17.4.2 Canada: Market Size & Forecast
18 Europe
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Drug Class Segmentation
18.3.1 Market Snapshot & Growth Engine
18.4 Key Countries
18.4.1 Germany: Market Size & Forecast
18.4.2 UK: Premature Ejaculation Therapeutics Market Size & Forecast
18.4.3 France: Market Size & Forecast
18.4.4 Italy: Premature Ejaculation Therapeutics Market Size & Forecast
18.4.5 Spain: Market Size & Forecast
19 APAC
19.1 Market Overview
19.2 Market Size & Forecast
19.3 Drug Class Segmentation
19.3.1 Market Snapshot & Growth Engine
19.4 Key Countries
19.4.1 Japan: Premature Ejaculation Therapeutics Market Size & Forecast
19.4.2 India: Market Size & Forecast
19.4.3 China: Premature Ejaculation Therapeutics Market Size & Forecast
19.4.4 Australia: Market Size & Forecast
19.4.5 South Korea: Premature Ejaculation Therapeutics Market Size & Forecast
20 Latin America
20.1 Market Overview
20.2 Market Size & Forecast
20.3 Drug Class Segmentation
20.3.1 Market Snapshot & Growth Engine
20.4 Key Countries
20.4.1 Brazil: Premature Ejaculation Therapeutics Market Size & Forecast
20.4.2 Mexico: Market Size & Forecast
20.4.3 Argentina: Premature Ejaculation Therapeutics Market Size & Forecast
21 Middle East & Africa
21.1 Market Overview
21.2 Market Size & Forecast
21.3 Drug Class Segmentation
21.3.1 Market Snapshot & Growth Engine
21.4 Key Countries
21.4.1 Turkey: Premature Ejaculation Therapeutics Market Size & Forecast
21.4.2 Saudi Arabia: Market Size & Forecast
21.4.3 South Africa: Premature Ejaculation Therapeutics Market Size & Forecast
21.4.4 Iran: Market Size & Forecast
22 Competitive Landscape
22.1 Competition Overview
22.2 Market Share Analysis
22.2.1 Absorption Pharmaceuticals
22.2.2 Innovus Pharmaceuticals
22.2.3 Pfizer
22.2.4 Plethora Solutions
23 Key Company Profiles
23.1 Absorption Pharmaceuticals
23.1.1 Business Overview
23.1.2 Product Offerings
23.1.3 Key Strategies
23.1.4 Key Strengths
23.1.5 Key Opportunities
23.2 Innovus Pharmaceuticals
23.2.1 Business Overview
23.2.2 Product Offerings
23.2.3 Key Strategies
23.2.4 Key Strengths
23.2.5 Key Opportunities
23.3 Pfizer
23.3.1 Business Overview
23.3.2 Product Offerings
23.3.3 Key Strategies
23.3.4 Key Strengths
23.3.5 Key Opportunities
23.4 Plethora Solutions Holdings
23.4.1 Business Overview
23.4.2 Product Offerings
23.4.3 Key Strategies
23.4.4 Key Strengths
23.4.5 Key Opportunities
24 Other Prominent Vendors
24.1 Bayer
24.1.1 Business Overview
24.1.2 Product Offerings
24.1.3 Key Strategies
24.1.4 Key Strengths
24.1.5 Key Opportunities
24.2 Eli Lilly and Company
24.2.1 Business Overview
24.2.2 Product Offerings
24.2.3 Key Strategies
24.2.4 Key Strengths
24.2.5 Key Opportunities
24.3 GlaxoSmithKline
24.3.1 Business Overview
24.3.2 Product Offerings
24.3.3 Key Strategies
24.3.4 Key Strengths
24.3.5 Key Opportunities
24.4 MidasCare
24.4.1 Business Overview
24.4.2 Product Offerings
24.4.3 Key Strategies
24.4.4 Key Strengths
24.4.5 Key Opportunities
24.5 Momentum Management
24.5.1 Business Overview
24.5.2 Product Offerings
24.5.3 Key Strategies
24.5.4 Key Strengths
24.5.5 Key Opportunities
24.6 Pound International
24.6.1 Business Overview
24.6.2 Product Offerings
24.6.3 Key Strategies
24.6.4 Key Strengths
24.6.5 Key Opportunities
24.7 Reckitt Benckiser Group
24.7.1 Business Overview
24.7.2 Product Offerings
24.7.3 Key Strategies
24.7.4 Key Strengths
24.7.5 Key Opportunities
24.8 Recordati
24.8.1 Business Overview
24.8.2 Product Offerings
24.8.3 Key Strategies
24.8.4 Key Strengths
24.8.5 Key Opportunities
24.9 Royalty Pharma
24.9.1 Business Overview
24.9.2 Product Offerings
24.9.3 Key Strategies
24.9.4 Key Strengths
24.9.5 Key Opportunities
24.10 Shibari
24.10.1 Business Overview
24.10.2 Product Offerings
24.10.3 Key Strategies
24.10.4 Key Strengths
24.10.5 Key Opportunities
24.11 The Menarini Group
24.11.1 Business Overview
24.11.2 Product Offerings
24.11.3 Key Strategies
24.11.4 Key Strengths
24.11.5 Key Opportunities
25 Report Summary
25.1 Key Takeaways
25.2 Strategic Recommendations
26 Quantitative Summary
26.1 Drug Class
26.2 Route of Administration (RoA)
26.3 Geography
27 Appendix
27.1 Abbreviations
List of Exhibits
Exhibit 1 Segmentation of Global Premature Ejaculation Therapeutics Market
Exhibit 2 Market Size Calculation Approach 2019
Exhibit 3 Characteristics Associated with PE
Exhibit 4 Classification of PE
Exhibit 5 ISSM Classification of PE
Exhibit 6 Broader Classification of PE
Exhibit 7 Major PE Types
Exhibit 8 Differentiation of Symptoms in Different PE Sub-types
Exhibit 9 Most Common Psychological Causes for PE
Exhibit 10 Common Causative Factors for PE
Exhibit 11 PE Prevalence Rate across Geographies
Exhibit 12 ISSN Recommended Drug Classes for PE Treatment
Exhibit 13 ISSN Recommended Drug Class for the Treatment of PE
Exhibit 14 Key Considerations of PE Clinical Trials
Exhibit 15 Clinical Trial Considerations
Exhibit 16 Key Primary/Secondary Endpoints in PE Clinical Trials
Exhibit 17 Key Hurdles in Research & Innovation of Breakthrough PE Drugs
Exhibit 18 Impact of High Demand for Topical Drug Therapies for PE Treatment
Exhibit 19 Available Topical Forms of PE Topical Therapies
Exhibit 20 Benefits of Topical Drug Delivery System for PE
Exhibit 21 Impact of Presence of High Unmet Demand
Exhibit 22 Impact of Advancements in PE Drug Formulation Technology
Exhibit 23 Impact of Rising Prevalence/Incidence of PE
Exhibit 24 Prevalence Rate of PE in Different Region
Exhibit 25 Comparison of Prevalence Rates of PE and ED in Different Age Groups (%)
Exhibit 26 Number of Men with Premature Ejaculation in US and EU (million)
Exhibit 27 Global Diabetes Prevalence by Region 2015–2040 (million)
Exhibit 28 Global Cancer Incidence 2018
Exhibit 29 Increase in Global Prostate Cancer Incidence by Region 2012–2020 (thousand)
Exhibit 30 Increase in Global ED Prevalence 1995−2025 (million)
Exhibit 31 Impact of Wide Accessibility of OTC Drugs & General Off-label Drugs for PE
Exhibit 32 Popular Therapeutics Available for Premature Ejaculation Treatment in Market
Exhibit 33 PE OTC Drugs Marketing Channels
Exhibit 34 Impact of Low Effectiveness of Non-pharmacological PE Treatment
Exhibit 35 Effectiveness of Pharmacotherapy for PE Treatment
Exhibit 36 Major Drawbacks of Non-pharmacological PE Treatments
Exhibit 37 Impact of Increasing Awareness Campaigns & Initiatives for PE Treatment
Exhibit 38 Impact of Availability of Alternative Treatment Options for PE
Exhibit 39 Popular Alternative Methods for PE Treatment
Exhibit 40 Impact of Low Treatment-Seeking Patient Pool
Exhibit 41 Number of Men with PE 2018 (million)
Exhibit 42 Key Factors Restricting PE Treatment Adoption
Exhibit 43 Major Surveys to Indicate Low PE Treatment Seeking Population
Exhibit 44 South Korean Survey Results on Urologists' PE Treatment Rates Per Week in 2012 (%)
Exhibit 45 Impact of Adverse Effects of PE Therapeutics
Exhibit 46 Common Adverse Effects of Drugs Recommended for PE
Exhibit 47 Impact of Clinical Trial Withdrawals/Terminations & Inactive Clinical Studies
Exhibit 48 Key Common Challenges Associated with Clinical Trial Withdrawals/Terminations
Exhibit 49 Global Premature Ejaculation Therapeutics Market Snapshot
Exhibit 50 Global Premature Ejaculation Therapeutics Market 2019–2025 ($ million)
Exhibit 51 Global Premature Ejaculation Therapeutics Market by Geography
Exhibit 52 Global Premature Ejaculation Therapeutics Market by Drug Class
Exhibit 53 Global Premature Ejaculation Therapeutics Market by ROA
Exhibit 54 Five Forces Analysis 2019
Exhibit 55 Incremental Growth by Drug Class 2019 & 2025
Exhibit 56 Global Premature Ejaculation Therapeutics Market by Drug Class
Exhibit 57 Global Market by Drug Class: Incremental Growth
Exhibit 58 Global Market by Drug Class: Absolute Growth
Exhibit 59 Global Market by Drug Class 2019−2025 ($ million)
Exhibit 60 Global Market by Drug Class 2019−2025 (%)
Exhibit 61 Common SSRIs for Treating PE
Exhibit 62 Global PE Therapeutics Market by SSRIs: Incremental & Absolute Growth Comparison
Exhibit 63 Comparison of Varying Efficacy Rates of Off-label SSRIs
Exhibit 64 Global SSRIs Market 2019–2025 ($ million)
Exhibit 65 Global PE Therapeutics Market by PDE5 Inhibitors: Incremental & Absolute Growth Comparison
Exhibit 66 Major PDE5i Drug Brands as Off-label PE Medications
Exhibit 67 Global PDE5 Inhibitors Market 2019–2025 ($ million)
Exhibit 68 Global PE Therapeutics Market by Anesthetic Agents: Incremental & Absolute Growth Comparison
Exhibit 69 Common Active Ingredients in Topical Anesthetic Formulations
Exhibit 70 Global Anesthetic Market 2019–2025 ($ million)
Exhibit 71 Global PE Therapeutics Market by Others Drugs: Incremental & Absolute Growth Comparison
Exhibit 72 Several Drug Classes Used for Treating Premature Ejaculation
Exhibit 73 Global Others Drugs Market 2019–2025 ($ million)
Exhibit 74 Incremental Growth by ROA 2019 & 2025
Exhibit 75 Global Premature Ejaculation Therapeutics Market by ROA
Exhibit 76 Global Market by ROA: Incremental Growth
Exhibit 77 Global Market by ROA: Absolute Growth
Exhibit 78 Global Market by ROA 2019−2025 ($ million)
Exhibit 79 Global Market by ROA 2019−2025 (%)
Exhibit 80 Oral Premature Ejaculation Treatment Market: Incremental & Absolute Growth
Exhibit 81 Major Oral Therapeutics Recommended for PE
Exhibit 82 Advantages of Oral PE Drugs
Exhibit 83 Global Oral PE Therapeutics Market 2019–2025 ($ million)
Exhibit 84 Available Topical Forms of PE Topical Therapies
Exhibit 85 Global PE Therapeutics Market by Topical ROA: Incremental & Absolute Growth
Exhibit 86 Benefits of Topical PE Drugs
Exhibit 87 Global Topical Market 2019–2025 ($ million)
Exhibit 88 Incremental Growth by Geography 2019 & 2025
Exhibit 89 Global Premature Ejaculation Therapeutics Market by Geography
Exhibit 90 Global Market by Geography 2019: Key Countries ($ million)
Exhibit 91 Global Market by Geography: Incremental Growth
Exhibit 92 Global Market by Geography: Absolute Growth
Exhibit 93 Global Market by Geography 2019−2025 ($ million)
Exhibit 94 Global Market by Geography 2019−2025 (%)
Exhibit 95 Premature Ejaculation Therapeutics Market in North America in 2019
Exhibit 96 North America Market: Incremental & Absolute Growth
Exhibit 97 Market in North America 2019–2025 ($ million)
Exhibit 98 Incremental Growth by Drug Class 2019 & 2025
Exhibit 99 North America Market by Drug Class 2019−2025 ($ million)
Exhibit 100 North America Market by Drug Class 2019−2025 (%)
Exhibit 101 Incremental Growth in North America 2019 & 2025
Exhibit 102 Number of People with Various Male Urologic Disorders in US
Exhibit 103 Market in US 2019–2025 ($ million)
Exhibit 104 Market in Canada 2019–2025 ($ million)
Exhibit 105 Premature Ejaculation Therapeutics Market in Europe 2019
Exhibit 106 Europe Market: Incremental & Absolute Growth
Exhibit 107 Market in Europe 2019–2025 ($ million)
Exhibit 108 Incremental Growth by Drug Class 2019 & 2025
Exhibit 109 Europe Market by Drug Class 2019−2025 ($ million)
Exhibit 110 Europe Market by Drug Class 2019−2025 (%)
Exhibit 111 Incremental Growth in Europe 2019 & 2025
Exhibit 112 Prevalence of PE in Men Aged 18−64 Years in Germany (%)
Exhibit 113 Market in Germany 2019–2025 ($ million)
Exhibit 114 Market in UK 2019–2025 ($ million)
Exhibit 115 Market in France 2019–2025 ($ million)
Exhibit 116 Market in Italy 2019–2025 ($ million)
Exhibit 117 Market in Spain 2019–2025 ($ million)
Exhibit 118 APAC Premature Ejaculation Therapeutics Market: Incremental & Absolute Growth
Exhibit 119 Market in APAC 2019
Exhibit 120 Market in APAC 2019–2025 ($ million)
Exhibit 121 Incremental Growth by Drug Class 2019 & 2025
Exhibit 122 APAC Market by Drug Class 2019−2025 ($ million)
Exhibit 123 APAC Market by Drug Class 2019−2025 (%)
Exhibit 124 Incremental Growth in APAC 2019 & 2025
Exhibit 125 Market in Japan 2019–2025 ($ million)
Exhibit 126 Market in India 2019–2025 ($ million)
Exhibit 127 Market in China 2019–2025 ($ million)
Exhibit 128 Market in Australia 2019–2025 ($ million)
Exhibit 129 Market in South Korea 2019–2025 ($ million)
Exhibit 130 Premature Ejaculation Therapeutics Market in Latin America 2019
Exhibit 131 Latin America Market: Incremental & Absolute Growth
Exhibit 132 Market in Latin America 2019–2025 ($ million)
Exhibit 133 Incremental Growth by Drug Class 2019 & 2025
Exhibit 134 Latin America Market by Drug Class 2019−2025 ($ million)
Exhibit 135 Latin America Market by Drug Class 2019−2025 (%)
Exhibit 136 Incremental Growth in Latin America 2019 & 2025
Exhibit 137 Market in Brazil 2019–2025 ($ million)
Exhibit 138 Market in Mexico 2019–2025 ($ million)
Exhibit 139 Market in Argentina 2019–2025 ($ million)
Exhibit 140 Premature Ejaculation Therapeutics Market in MEA 2019
Exhibit 141 MEA Market: Incremental & Absolute Growth
Exhibit 142 Market in MEA 2019–2025 ($ million)
Exhibit 143 Incremental Growth by Drug Class 2019 & 2025
Exhibit 144 MEA Market by Drug Class 2019−2025 ($ million)
Exhibit 145 MEA Market by Drug Class 2019−2025 (%)
Exhibit 146 Incremental Growth in MEA 2019 & 2025
Exhibit 147 Prevalence of PE in Turkish Population (%)
Exhibit 148 Market in Turkey 2019–2025 ($ million)
Exhibit 149 Market in Saudi Arabia 2019–2025 ($ million)
Exhibit 150 Market in South Africa 2019–2025 ($ million)
Exhibit 151 Market in Iran 2019–2025 ($ million)
Exhibit 152 Global Premature Ejaculation Therapeutics Market: Vendors Market Share 2019
Exhibit 153 Pfizer: R&D Expenditure 2017−2019 ($ million)
Exhibit 154 Pfizer: Revenue by Segments 2018 & 2019 ($ million)
Exhibit 155 Pfizer: Revenue by Geography 2018 (%)
List of Tables
Table 1 Key Caveats
Table 2 Currency Conversion 2013−2019
Table 3 Popular Definitions of Premature Ejaculation
Table 4 Summary of PE Epidemiology Studies
Table 5 Recommended/Optional Questions to Establish Diagnosis and Treatment of PE
Table 6 Summary of PE Validated Questionnaires
Table 7 Summary of Commonly Recommended PE Drugs
Table 8 Key Pipeline PE Drug Molecules
Table 9 Epelsiban: Product Profile
Table 10 IX-01 Product Profile
Table 11 DA-8031 Product Profile
Table 12 NH02D Product Profile
Table 13 Key Dormant/Terminated/Withdrawn PE Pipeline Drug Molecules
Table 14 Key Topical Therapy PE Drugs by Type of Formulation
Table 15 Major Unmet Need in PE Market
Table 16 Marketed PE Drugs with Meter-Dose Delivery Systems
Table 17 Notable Awareness Campaigns Initiated for PE in Recent Years
Table 18 Key Terminated/Withdrawn & Inactive Investigational PE Drugs
Table 19 SSRIs Dose in PE Treatment
Table 20 List of Popular SSRIs for PE
Table 21 List of Popular PDE5 Inhibitors For PE
Table 22 Commonly Used Topical PE OTC Ester/Amide Anesthetic
Table 23 List of Popular Anesthetic Agents for Treating PE
Table 24 Significant Players Offering Oral Drugs for PE Treatment
Table 25 Comparison of Popular Topical Anesthetics for PE
Table 26 North America Premature Ejaculation Therapeutics Market by Drug Class 2019−2025 ($ million)
Table 27 Key Campaigns Launched in Europe to Improve Awareness of PE
Table 28 Europe Premature Ejaculation Therapeutics Market by Drug Class 2019−2025 ($ million)
Table 29 APAC Premature Ejaculation Therapeutics Market by Drug Class 2019−2025 ($ million)
Table 30 Latin America Premature Ejaculation Therapeutics Market by Drug Class 2019−2025 ($ million)
Table 31 MEA Premature Ejaculation Therapeutics Market by Drug Class 2019−2025 ($ million)
Table 32 Competitive Structure Analysis of Global Premature Ejaculation Therapeutics Market 2019
Table 33 Global Premature Ejaculation Therapeutics Market Vendor Ranking 2019
Table 34 Absorption Pharmaceuticals: Major Product Offerings
Table 35 Innovus Pharmaceuticals: Major Product Offerings
Table 36 Pfizer: Major Product Offerings
Table 37 Plethora Solutions Holdings: Major Product Offerings
Table 38 Bayer: Major Product Offerings
Table 39 Eli Lilly and Company: Major Product Offerings
Table 40 GlaxoSmithKline: Major Product Offerings
Table 41 MidasCare: Major Product Offerings
Table 42 Momentum Management: Major Product Offerings
Table 43 Pound International: Major Product Offerings
Table 44 Reckitt Benckiser Group: Major Product Offerings
Table 45 Recordati: Major Product Offerings
Table 46 Royalty Pharma: Major Product Offerings
Table 47 Shibari: Major Product Offerings
Table 48 The Menarini Group: Major Product Offerings
Table 49 Global Premature Ejaculation Therapeutics Market by Drug Class 2019−2025 ($ million)
Table 50 Global Market by Drug Class 2019−2025 (%)
Table 51 Global Premature Ejaculation Therapeutics Market by ROA 2019−2025 ($ million)
Table 52 Global Market by ROA 2019−2025 (%)
Table 53 Global Premature Ejaculation Therapeutics Market by Geography 2019−2025 ($ million)
Table 54 Global Market by Geography 2019−2025 (%)
Single User Licence
5 User Licence
Corporate Licence
Datasheet Licence
"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."
